Dianthus Therapeutics, Inc. /DE/ (DNTH) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2528281080
Dianthus Therapeutics, Inc. /DE/ financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.04 m USD |
| Operating income | -177.93 m USD |
| EBIT | -172.29 m USD |
| Net income | -162.34 m USD |
| Diluted EPS – continuing operations | -4.20 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
More stocks
- Organization of Football Prognostics SA (OPAP.AT)
- Mitsubishi Gas Chemical Co Inc (4182.T)
- Athens International Airport SA (AIA.AT)
- Brookfield Infrastructure Corp (BIPC)
- Mazda Motor Corp (7261.T)
- 3SBio Inc (1530.HK)
- Copperstone Resources AB (publ) (COPP B.ST)
- SCHOTT Pharma AG & Co KgaA (1SXP.DE)
- GDS Holdings Ltd (9698.HK)
- Doosan Pref Shs (000155.KS)
- Henan Pinggao Electric Co Ltd (600312.SS)
- Freshworks Inc. (FRSH)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.